FDA's Faster CRISPR Path

CRISPR is a gene-editing tool that works like molecular scissors, cutting DNA at a chosen spot so a faulty gene can be fixed. The Food and Drug Administration is now proposing a new review path for one-off gene medicines built for patients with ultra-rare mutations. (fda.gov) The agency’s draft guidance, issued in February 2026, says developers could use a “plausible mechanism” approach to show that closely related therapies should work in similar patients even when a standard randomized trial is impossible. The comment period on that draft runs through April 27, 2026. (federalregister.gov) In plain terms, the framework would let researchers combine evidence from lab studies, manufacturing data, natural-history records, and small clinical datasets instead of starting from zero for every mutation. The FDA says the goal is to generate enough evidence of safety, effectiveness, and product quality for an individualized therapy aimed at a specific genetic condition. (fda.gov) The push follows the case of KJ Muldoon, an infant at Children’s Hospital of Philadelphia with severe carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disease. KJ received the first dose of a custom CRISPR treatment in February 2025, between six and seven months of age, and CHOP said in May 2025 that he was growing well after the treatment was administered safely. (chop.edu) That case showed what bespoke gene editing can do, but it also showed how hard the current system is to scale. STAT reported in January 2026 that KJ’s therapy required a six-month effort involving dozens of scientists across North America and large support from government and industry. (statnews.com) FDA officials tied the February draft to a broader policy shift first outlined in a November 2025 New England Journal of Medicine article by Commissioner Marty Makary and biologics chief Vinay Prasad. BioPharma Dive reported that the pathway is meant for serious diseases so rare that randomized clinical trials may not be feasible at all. (biopharmadive.com) The agency has already started filling in the technical details around that policy. On April 14, 2026, the FDA issued a second draft guidance on genome-editing safety that recommends next-generation sequencing methods to check for off-target edits and other signs of genome damage in both cells edited outside the body and therapies delivered directly into tissue. (fda.gov) The framework also leans on shared evidence, not just shared technology. Faegre Drinker said the draft promotes data-sharing and the use of well-characterized natural-history data to build externally controlled studies, which could let later therapies on the same platform rely in part on what earlier patients already taught regulators. (faegredrinker.com) Not everyone is fully on board with the faster route. STAT reported that bioethicist Holly Fernandez Lynch welcomed a new way to clear treatments for tiny patient groups but raised concerns about unintended consequences if evidence standards become too thin for products that permanently alter DNA. (statnews.com) For now, the proposal is still draft guidance, not a final rule. But by April 2026 the FDA had moved from a journal essay to a formal framework and a companion safety document, giving developers, hospitals, and patient groups a concrete path to argue over before the agency decides what the final version will require. (fda.gov)